Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia ; volume:10 ; number:1 ; day:23 ; month:6 ; year:2018 ; pages:1-7 ; date:12.2018
Alzheimer's research & therapy ; 10, Heft 1 (23.6.2018), 1-7, 12.2018
- Urheber
-
Chakraborty, Ananya
- Beteiligte Personen und Organisationen
-
Chatterjee, Madhurima
Twaalfhoven, Harry
Del Campo Milan, Marta
Teunissen, Charlotte E.
Scheltens, Philip
Fontijn, Ruud D.
van Der Flier, Wiesje M.
de Vries, Helga E.
SpringerLink (Online service)
- DOI
-
10.1186/s13195-018-0385-8
- URN
-
urn:nbn:de:101:1-2018090201505205601369
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chakraborty, Ananya
- Chatterjee, Madhurima
- Twaalfhoven, Harry
- Del Campo Milan, Marta
- Teunissen, Charlotte E.
- Scheltens, Philip
- Fontijn, Ruud D.
- van Der Flier, Wiesje M.
- de Vries, Helga E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients